637-07-0 Usage
Uses
1. Used in Pharmaceutical Industry:
Clofibrate is used as a vasodilator for improving blood flow and reducing blood pressure.
2. Used in Lipid-Lowering Therapy:
Clofibrate is used as an inhibitor of cholesterol biosynthesis to lower cholesterol levels in the body.
3. Used in Cardiovascular Disease Treatment:
Clofibrate is used as a lipid-lowering agent (antilipidemic) for controlling high cholesterol (anticholesteremic) and triacylglyceride levels in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, thereby reducing VLDL levels. It is indicated only in subjects with increased concentrations of VLDL and intermediate-density lipoproteins (IDL) who have failed to respond adequately to gemfibrozil or nicotinic acid.
4. Used in Neurohypophyseal Diabetes Insipidus Treatment:
Clofibrate has been used to prevent or control polydipsia, polyuria, and dehydration in a limited number of patients with mild to moderate neurohypophyseal diabetes insipidus.
Originator
Atromid-S,I.C.I.,UK,1963
Manufacturing Process
The ethyl p-chlorophenoxyisobutyrate may be obtained by heating a mixture
of 206 parts of dry p-chlorophenoxyisobutyric acid, 1,000 parts of ethanol and
40 parts of concentrated sulfuric acid under reflux during 5 hours. The alcohol
is then distilled off and the residue is diluted with water and extracted with
chloroform. The chloroform extract is washed with sodium hydrogen carbonate
solution, dried over sodium sulfate and the chloroform removed by distillation.
The residue is distilled under reduced pressure and there is obtained ethyl pchlorophenoxyisobutyrate, BP 148° to 150°C/20 mm.
The p-chlorophenoxyisobutyric acid used as starting material may be obtained
as follows. A mixture of 200 parts of p-chlorophenol, 1,000 parts of acetone
and 360 parts of sodium hydroxide pellets is heated under reflux and 240
parts of chloroform are gradually added at such a rate that the mixture
continues to reflux without further application of heat.
When addition is complete the mixture is heated under reflux during 5 hours
and then the acetone is removed by distillation. The residue is dissolved in
water, acidified with hydrochloric acid and the mixture extracted with
chloroform. The chloroform extract is stirred with sodium hydrogen carbonate
solution and the aqueous layer is separated. The alkaline extract is acidified
with hydrochloric acid and filtered. The solid product is drained free from oil
on a filter pump, then washed with petroleum ether (BP 40° to 60°C), and
dried at 50°C. The solid residue, MP 114° to 116°C, may be crystallized from
methanol (with the addition of charcoal) to give p-chlorophenoxyisobutyric
acid, MP 118° to 119°C.
Therapeutic Function
Antihyperlipidemic
World Health Organization (WHO)
Clofibrate, an antihyperlipidaemic agent, was introduced in 1967
and was subsequently extensively studied in the primary and secondary prevention
of ischaemic heart disease. Following reports, published in 1978, of increased
mortality among patients receiving clofibrate in a WHO-sponsored cooperative trial
concerned with the primary prevention of ischaemic heart disease, the drug was
withdrawn in some countries and its approved indications were severely restricted in many others. These restrictions have become the norm for more recently
developed analogues of clofibrate.
(Reference: (WHODI) WHO Drug Information, 2, 6, 1979)
Hazard
Questionable carcinogen; toxic; causes
nausea, vomiting, diarrhea, weakness, stiffness,
cramps, and muscle tenderness.
Biological Activity
PPAR agonist (EC 50 values are 50, 500 and > 100 μ M at PPAR α , PPAR γ and PPAR δ respectively). Antihyperlipoproteinemic.
Biochem/physiol Actions
Clofibrate is a peroxisome proliferated activated receptor α (PPARα) agonist. It is a fibric acid derivative and has a therapeutic effect on hypertriglyceridemia and hyperlipoproteinemia type III. Clofibrate participates in lowering the very-low-density lipoprotein (VLDL) and cholesterol levels in hyperlipoproteinemia type III patients. It facilitates the decrease of total serum bilirubin concentration in Gilbert′s syndrome.
Mechanism of action
The three structurally related fibrates available in the
United States are gemfibrozil (Lopid), fenofibrate
(Tricor) and clofibrate (Atromid-S).They share common
uses and toxicities. The fibrates typically lower VLDL
triglyceride by 40% or more and elevate plasma HDL
cholesterol by 10 to 15%. The reduction of plasma
triglycerides in humans appears due to increased lipoprotein
lipase (LPL) activity. The fibrates activate a nuclear
receptor (transcription factor) termed peroxisomal proliferation
activated receptor (PPAR) that is a member of
the steroid hormone receptor superfamily. PPAR increases
transcription of the LPL gene and decreases transcription
of the apolipoprotein CIII gene (apo CIII).
Since LPL is responsible for catabolism of VLDL triglyceride
and apo CIII is an inhibitor of LPL activity, the
combined consequences of these changes are increased
LPL activity and enhanced removal of triglyceride from
the circulation.
The elevation of HDL levels by fibrates may be due
to two drug actions: induced synthesis of apo-A1, the
principal apoprotein of HDL, and increased assembly
of new HDL particles in the circulation. Surface components
of VLDL contribute to formation of HDL, as
the VLDL particles are reduced in size through the action
of LPL.The increased rate of catabolism of VLDL
caused by the fibrates would provide more components
for assembly of HDL particles.
Pharmacokinetics
The pro-drug, fenofibrate, requires a longer time to reach peak concentrations compared with gemfibrozil. Because of
differences in aromatic substitution, fenofibrate also has a much longer half-life than gemfibrozil. As previously mentioned, the
2,5-dimethyl substitution in gemfibrozil is much more susceptible to oxidative metabolism than the para-chloro group present in
fenofibrate. Similar to HMGRIs, changes in lipid levels are not seen immediately, and up to 2 months may be required to reach maximal
clinical effects and to determine the overall clinical efficacy.
Fibrates have excellent bioavailability and are extensively bound to plasma proteins. Because food can significantly enhance their oral
absorption, these compounds should be taken either with or just before meals. Fenofibrate was available in Europe and elsewhere as
standard tablet and capsule formulations for many years before its approval and marketing in the United States, where it was introduced
only after the development of a micronized formulation that allowed better oral absorption, a lower daily dose, and once-daily
administration. A 67-mg dose of micronized fenofibrate is bioequivalent to a 100-mg dose of nonmicronized drug. Since that time, two
additional tablet formulations have been developed. Abbott Laboratories currently markets TriCor as 48- and 145-mg tablets. The 48-mg
formulation is equivalent to previous 54- and 67-mg formulations, and the 145-mg tablet is equivalent to previous 160- and 200-mg
formulations. As noted in Table 30.10, fenofibrate is currently available in all of these strengths.
Renal elimination is the primary route through which these compounds are excreted from the body. Patients with mild renal dysfunction
often can be managed with minor dosage adjustments, whereas those with severe impairment or renal failure may have to discontinue its
use.
Clinical Use
Clofibrate is the drug of choice in the treatment of typeIII hyperlipoproteinemias and may also be useful, to a lesserextent, in types IIb and IV hyperlipoproteinemias. The drugis not effective in types I and IIa.Clofibrate can lower plasma concentrations of both triglyceridesand cholesterol, but it has a more consistent clinicaleffect on triglycerides. It also affects lipoprotein plasmalevels by enhancing removal of triglycerides from the circulationand causes reduction of VLDL by stimulatinglipoprotein lipase to increase the catabolism of this lipoproteinto LDL. Clofibrate lowers triglyceride levels in theserum much more than cholesterol levels and decreases levelsof FFAs and phospholipids. The lowering of cholesterollevels may result from more than one mechanism. Clofibrateinhibits the incorporation of acetate into the synthesis ofcholesterol, between the acetate and mevalonate step, by inhibitingsn-glyceryl-3-phosphate acyltransferase. Clofibratealso regulates cholesterol synthesis in the liver by inhibitingmicrosomal reduction of 3-hydroxy-3-methylglutaryl-CoA(HMG-CoA), catalyzed by HMG-CoA reductase. Clofibratemay lower plasma lipids by means other than impairment ofcholesterol biosynthesis, such as increasing excretionthrough the biliary tract.
Side effects
The fibrates are generally well tolerated, with GI
distress being the most likely complaint. Other adverse
effects include myositis and erectile dysfunction, particularly
with clofibrate. There is ongoing concern about
the fibrates increasing the risk of gallstones, although
the extent of risk is unclear. Because clofibrate was associated
with increased mortality in early clinical trials,
it should be considered as a second-line drug.
Safety Profile
Poison by intravenous route.Moderately toxic by ingestion and other routes. Anexperimental teratogen. Other experimental reproductiveeffects. Reduces plasma lipid levels. Human systemiceffects by ingestion: muscle weakness, muscle spasms, andfever. Q
Synthesis
Clofibrate, ethyl ether 2-(4-chloropheoxy)-iso-butyric acid (20.2.2), is synthesized
by esterifying 2-(4-chlorophenoxy)-iso-butyric acid (20.2.1) with ethyl alcohol. This
is synthesized in a single-stage reaction from 4-chlorophenol, acetone, and chloroform in
the presence of an alkali, evidently by initial formation of chlorethone-trichloro-tert-butyl
alcohol, which under the reaction conditions is converted into (4-chlorophenoxy)trichlorotert-
butyl ether, and further hydrolyzed to the desired acid 20.2.1, which is further esterified
with ethanol in the presence of inorganic acid.
Drug interactions
The fibrates potentiate the actions of the coumarin
anticoagulants, such as warfarin, so care should be taken
to reduce the dose of simultaneously administered anticoagulants,
and plasma prothrombin should be frequently
measured until the level stabilizes. As mentioned
earlier, great care should be given to combining
a statin with a fibrate, since this combination may increase
the risk of myositis and perhaps rhabdomyolysis.
Environmental Fate
Clofibrate characteristically reduces plasma triglycerides by
lowering the concentration of VLDL within 2–5 days after
initiation of therapy. In a majority of patients, total cholesterol
and LDL concentrations in plasma fall slightly. However, some
patients who exhibit a large fall in VLDL may show a paradoxical
rise in LDL, resulting in minimal net effect on total
cholesterol levels.
The drug has several proposed antilipidemic actions,
including increased triglyceride and VLDL clearance, mobilization
of cholesterol from tissues, increased fecal excretion of
neutral sterols, decreased hepatic lipoprotein synthesis and/or
secretion, decreased free fatty acid release, and decreased
triglyceride synthesis. The precise mechanisms by which clofibrate
lowers serum concentrations of triglycerides and cholesterol
are not known.
Metabolism
The pro-drug fenofibrate undergoes rapid hydrolysis to produce fenofibric acid. This active metabolite can then be further metabolized
by oxidative or conjugative pathways. Gemfibrozil is slightly different in that it does not require initial bioactivation; however, similar to
fenofibric acid, it can be oxidized or conjugated. Oxidation of the aromatic methyl groups produces inactive hydroxymethyl and carboxylic
acid analogues. As a drug class, fibrates and their oxidized analogues are primarily excreted as glucuronide conjugates in the urine.
Oxidization requires the CYP3A4 isozyme; however, because of the ability of these compounds to be conjugated and eliminated either
with or without oxidation, drug interactions with other compounds affecting the CYP3A4 system are less important here than with other
drug classes.
Toxicity evaluation
Clofibrate is a clear, colorless liquid with a density of 1.14 g ml-1
(at 25°C). The boiling point of clofibrate is 148–150°C at
25mmHg. This drug is a stable, colorless to pale-yellow liquid
with a faint odor and characteristic taste. Its melting point is
below 25°C, it is soluble in common solvents but not in water,
and its solubility or log P (octanol/water) is 3.620.
Check Digit Verification of cas no
The CAS Registry Mumber 637-07-0 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 6,3 and 7 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 637-07:
(5*6)+(4*3)+(3*7)+(2*0)+(1*7)=70
70 % 10 = 0
So 637-07-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3
637-07-0Relevant articles and documents
Oxidative Photochlorination of Electron-Rich Arenes via in situ Bromination
Düsel, Simon Josef Siegfried,K?nig, Burkhard
supporting information, p. 1491 - 1495 (2019/04/30)
Electron-rich arenes are oxidatively photochlorinated in the presence of catalytic amounts of bromide ions, visible light, and 4CzIPN as organic photoredox catalyst. The substrates are brominated in situ in a first photoredox-catalyzed oxidation step, followed by a photocatalyzed ipso-chlorination, yielding the target compounds in high ortho/para regioselectivity. Dioxygen serves as a green and convenient terminal oxidant. The use of aqueous hydrochloric acid as the chloride source reduces the amount of saline by-products.
INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION
-
Paragraph 000169; 000186, (2020/03/05)
The compounds of Formula I, II, and III along with their stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof are described in the present disclosure. The said compounds restore immune activation in case of infections or a disease associated with an HIV infection in a subject in need thereof.
Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof
-
Paragraph 0147; 0148; 0149; 0150, (2019/11/12)
The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.
Synthesis and computer-aided analysis of the role of linker for novel ligands of the 5-HT6 serotonin receptor among substituted 1,3,5-triazinylpiperazines
?a?ewska, Dorota,Kurczab, Rafa?,Wi?cek, Ma?gorzata,Sata?a, Grzegorz,Kie?-Kononowicz, Katarzyna,Handzlik, Jadwiga
, p. 319 - 325 (2018/12/11)
A series of 2-amino-4-(4-methylpiperazin-1-yl)-1,3,5-triazines was designed based on previously published 2-amino-4-benzyl-(4-methylpiperazin-1-yl)-1,3,5-triazines in order to evaluate the role of a linker between the triazine moiety and an aromatic substituent for the human serotonin 5-HT6 receptor affinity. As new linkers two carbon atoms (ethyl or ethenyl) or an oxyalkyl chain (methoxy, 2-ethoxy, 2-propoxy) were introduced. Affinities of the compounds for the 5-HT6R as the main target, and for the 5-HT1AR, 5-HT7R and D2R as competitive ones, were determined in the radioligand binding assays. Docking to the 5-HT6R homology model was performed to support SAR analysis. Results showed that the branching of the methoxyl linker increased affinity for the human 5-HT6R whereas an unsaturated bond within the linker dramatically reduced desirable activity. Both experimental and theoretical studies confirmed the previously postulated beneficial role of the aromatic size for interaction with the 5-HT6R. Thus, the largest naphthyl moiety yielded the highest activity. In particular, 4-(4-methylpiperazin-1-yl)-6-(1-(naphthalen-1-yloxy)ethyl)-1,3,5-triazin-2-amine (24), the most potent 5-HT6R agent found (Ki = 23 nM), can be a new lead structure for further search and development.
Design, synthesis of novel, potent, selective, orally bioavailable adenosine A2A receptor antagonists and their biological evaluation
Basu, Sujay,Barawkar, Dinesh A.,Thorat, Sachin,Shejul, Yogesh D.,Patel, Meena,Naykodi, Minakshi,Jain, Vaibhav,Salve, Yogesh,Prasad, Vandna,Chaudhary, Sumit,Ghosh, Indraneel,Bhat, Ganesh,Quraishi, Azfar,Patil, Harish,Ansari, Shariq,Menon, Suraj,Unadkat, Vishal,Thakare, Rhishikesh,Seervi, Madhav S.,Meru, Ashwinkumar V.,De, Siddhartha,Bhamidipati, Ravi K.,Rouduri, Sreekanth R.,Palle, Venkata P.,Chug, Anita,Mookhtiar, Kasim A.
supporting information, p. 681 - 694 (2017/02/05)
Our initial structure-activity relationship studies on 7-methoxy-4-morpholino-benzothiazole derivatives featured by aryloxy-2-methylpropanamide moieties at the 2-position led to identification of compound 25 as a potent and selective A2A adenosine receptor (A2AAdoR) antagonist with reasonable ADME and pharmacokinetic properties. However, poor intrinsic solubility and low to moderate oral bioavailability made this series unsuitable for further development. Further optimization using structure-based drug design approach resulted in discovery of potent and selective adenosine A2A receptor antagonists bearing substituted 1-methylcyclohexyl-carboxamide groups at position 2 of the benzothiazole scaffold and endowed with better solubility and oral bioavailability. Compounds 41 and 49 demonstrated a number of positive attributes with respect to in vitro ADME properties. Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat. Further, compound 49 displayed oral efficacy in 6-OHDA lesioned rat model of Parkinson diseases.
Nitroethylene-containing ester compound as well as preparation method and application thereof
-
Paragraph 0113; 0214-0217, (2017/08/30)
The invention relates to the field of fructose-1,6-biphosphatase inhibitors, and specifically discloses a nitroethylene-containing ester compound. The ester compound is the compound as shown in a formula (1). The invention further discloses a preparation method of the compound as shown in the formula (1). The invention further discloses another nitroethylene-containing ester compound which is the compound as shown in the formula (2). The invention further discloses a preparation method of the compound as shown in the formula (2). The invention further provides application of the nitroethylene-containing ester compounds or pharmaceutically acceptable salt in preparation of medicines such as the medicine for inhibiting fructose-1,6-biphosphatase, and the medicine for treating or preventing gluconeogenesis metabolic disease or thrombus diseases.
Room temperature C(sp2)-H oxidative chlorination: Via photoredox catalysis
Zhang, Lei,Hu, Xile
, p. 7009 - 7013 (2017/10/05)
Photoredox catalysis has been developed to achieve oxidative C-H chlorination of aromatic compounds using NaCl as the chlorine source and Na2S2O8 as the oxidant. The reactions occur at room temperature and exhibit exclusive selectivity for C(sp2)-H bonds over C(sp3)-H bonds. The method has been used for the chlorination of a diverse set of substrates, including the expedited synthesis of key intermediates to bioactive compounds and a drug.
AMINE AND ETHER COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR
-
Page/Page column 36-37, (2009/10/18)
Compounds which modulate the CB2 receptor are disclosed. The compounds are useful for treating CB2 receptor-mediated diseases such as pain.
2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION
-
Page/Page column 32-33, (2008/12/07)
Compounds of the present disclosure are 2,2,2-tri-substituted acetamide derivatives of formula (I), its polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, useful as Glucokinase activator. Processes of their preparation are also described in the disclosure. The disclosure also describes method to characterize partial glucokinase activators.
Liquid-phase synthesis of 2-methyl-2-aryloxypropanoic acid derivatives from poly(ethylene glycol) supported 2-bromo-2-methylpropanoate
Huang, Bin,Huang, Pei-Gang,Sheng, Shou-Ri,Wang, Qiu-Ying,Guo, Lei,Jiang, Shao-Hua
, p. 575 - 578 (2008/02/11)
An efficient liquid-phase synthesis of 2-methyl-2-aryloxypropanoic acid derivatives with good yields and high purity on soluble polyethylene glycol (PEG) has been developed by treatment of PEG-bound 2-bromo-2-methylpropanoate with phenoxides in the presence of a catalytic amount of NBu4I and KI, and subsequent cleavage from the PEG.
